-
J.P. Morgan Reports "Generally Soft" 1Q Results For Charles River Laboratories
Wednesday, May 4, 2011 - 9:07am | 103According to J.P. Morgan, Charles River Laboratories (NYSE: CRL) 1Q results were generally soft (net sales -2.2% y/y), but showed q/q improvement (+1.5% q/q) against diminished expectations (consensus $279M), with cost initiatives and share repurchases providing cushion on the bottom line. J.P....
-
Goldman Sachs Reports Charles River Laboratories EPS Higher Than Expected (CRL)
Wednesday, May 4, 2011 - 8:51am | 89According to Goldman Sachs, Charles River Laboratories (NYSE: CRL) reported 1Q EPS of $0.61 versus $0.55 EPS estimated by GS. In the report, Goldman Sachs said, "Results were helped by cost-savings actions along with share repurchases and management made no change to its non-GAAP EPS range of $2....
-
Jefferies Lowers PT On PRXL To $26.50
Wednesday, May 4, 2011 - 8:50am | 111Jefferies has lowered its price target on PAREXEL International (NASDAQ: PRXL) from $30 to $26.50, citing concerns of the company's revenue revisions. Says Jefferies, in the report, “It is difficult to go back to this well, after two downward revenue revisions. However, management did provide...
-
Global Hunter Securities Raises PT On MDVN To $30
Wednesday, May 4, 2011 - 8:26am | 277Global Hunter Securities has raised its price target from $24 to $30 on Medivation (NASDAQ: MDVN) in its preview of Q1:11 results which are to be released after the market close on Friday. In the report, Global Hunter Securities writes, “We believe the focus of the earnings call will be on an...
-
Benchmark Raises PT, Upgrades Rating On ERES
Wednesday, May 4, 2011 - 8:05am | 124Benchmark is raising its price target from $5 to $7 on eResearch Technology Inc. (NASDAQ: ERES) and has upgraded its rating from Sell to Hold on the stock. Says Benchmark, in the report, “[ERES] reported strong Q1 contract bookings and non-GAAP earnings, but cancellations soared and management...
-
Jefferies Raises PT On Bio-Rad Laboratories To $145
Wednesday, May 4, 2011 - 7:39am | 27Jefferies & Company has raised the price target on Bio-Rad Laboratories (NYSE: BIO) from $127 to $145 and maintains its Buy rating.
-
Jefferies Lowers PT On PAREXEL To $26.50
Wednesday, May 4, 2011 - 7:08am | 27Jefferies & Company has lowered the price target on PAREXEL International (NASDAQ: PRXL) from $30 to $26.50 and maintains its Buy rating.
-
CEOWORLD Most Actives Top Healthcare stocks picks on 5/4/11- GENE, SPPI, AMRI, GTXI, AFFX,KV.A, SCLN, CBM, CERS, CEPH, TEVA, THC, JNJ
Wednesday, May 4, 2011 - 6:59am | 1424Gainers (% price change): Genetic Tech. Ltd. (ADR) (GENE) engaged in a diagnostic product business is trading at a price of $8.18, a dramatic change of +2.41 (41.77%) from its previous day's close. Currently, the company has a Market capitalization (total value of a company in the stock market)...
-
JP Morgan Raises PT On Charles River Laboratories To $38
Wednesday, May 4, 2011 - 6:42am | 28JP Morgan has raised the price target on Charles River Laboratories (NYSE: CRL) from $34 to $38 and maintains its Neutral rating.
-
JP Morgan Downgrades AMAG Pharmaceuticals To Neutral, PT To $20
Wednesday, May 4, 2011 - 6:39am | 28JP Morgan has downgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Overweight to Neutral and has lowered the price target from $28 to $20.
-
Charles River Labs Reports EPS of $0.61 vs. $0.55 Estimate; Revenues $285.8M vs. $279.17M Estimate
Tuesday, May 3, 2011 - 4:30pm | 23Charles River Labs (NYSE: CRL) Reports EPS of $0.61 vs. $0.55 Estimate; Revenues $285.8M vs. $279.17M Estimate
-
Bio-Rad Labs Reports EPS of $1.16 vs. $1.32 Estimate; Revenues $485.1M vs. $482.11M Estimate
Tuesday, May 3, 2011 - 4:21pm | 22Bio-Rad Labs (NYSE: BIO) Reports EPS of $1.16 vs. $1.32 Estimate; Revenues $485.1M vs. $482.11M Estimate
-
Morning Market Losers (PRXL, CSC, RIC, PFED)
Tuesday, May 3, 2011 - 10:01am | 110PAREXEL International Corporation (NASDAQ: PRXL) fell 17.69% to $22.24 at 10:00 am. PRXL lowered its profit and revenue guidance for fiscal 2011. Computer Sciences Corporation (NYSE: CSC) shares dropped 13.57% to $43.69. CSC lowered its 2011 profit projections for the second time in three months...
-
SearCare Life Sciences: Hearing Rumors Of A $17M Contract (SRLS) Read more: http://www.benzinga.com/news/contracts/11/05/1052272/searcare-life-sciences-hearing-rumors-of-a-17m-contract-srls#ixzz1LISczCgA
Tuesday, May 3, 2011 - 9:44am | 36SearCare Life Sciences: Hearing Rumors Of A $17M Contract (NASDAQ: SRLS) https://www.fbo.gov/?s=opportunity&mode=form&id=570e34d0980072e3405aa08cdaaa7862&tab=core&_cview=1
-
SearCare Life Sciences: Hearing Rumors Of A $17M Contract (SRLS)
Tuesday, May 3, 2011 - 9:43am | 36SearCare Life Sciences: Hearing Rumors Of A $17M Contract (NASDAQ: SRLS) https://www.fbo.gov/?s=opportunity&mode=form&id=570e34d0980072e3405aa08cdaaa7862&tab=core&_cview=1